Effects of Methylphenidate on the Catecholaminergic System in Attention-Deficit/Hyperactivity Disorder
The DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.
Abstract
Stimulants are part of the standard-of-care treatment for attention-deficit/hyperactivity disorder (ADHD). Methylphenidate, with a history of use spanning approximately 5 decades, is a first-line stimulant treatment for ADHD. Methylphenidate chiefly affects the prefrontal cortex and striatum, the mechanism of action being modulation of catecholaminergic tone. Methylphenidate treatment produces an increase in dopamine (DA) signaling through multiple actions, including blockade of the DA reuptake transporter and amplification of DA response duration, disinhibition of DA D2 autoreceptors and amplification of DA tone, and activation of D1 receptors on the postsynaptic neuron. The actions of methylphenidate may also be mediated by stimulation of the noradrenergic alpha2 receptor and DA D1 receptor in the cortex. The role of other neurotransmitters such as histamine, acetylcholine, serotonin, and alpha-agonists in modulating catecholamine pathophysiology in ADHD and ADHD treatment needs to be elucidated. Overall, the changes in catecholaminergic tone clinically manifest as improvements in attention deficit, distractibility, and motor hyperactivity in patients with ADHD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DA accumulation after MPH blockade of DAT induces disinhibition (upregulation) of the presynaptic receptor DRD2 (dopaminergic neuron) and activates D1 receptors on the postsynaptic neuron that uptake DA, continuing the neuronal transmission and therefore improving attention, focus and organized thoughts and actions [172, 173].”
From Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review (2022) · cites this paper as [173]
In the citing paper
“Psychostimulants, such as methylphenidate, followed by dexamphetamines, are first-line pharmacologic treatment for ADHD and reduce symptoms in about 70% of patients 11, 12.”
From Effects of stimulants on brain function in attention-deficit/hyperactivity disorder: a systematic review and meta-analysis (2014) · cites this paper as [11]
In the citing paper
“The therapeutic dose of MPH works primarily via (1) increasing DA signaling through multiple actions, including DAT blockade in the PFC, and significantly enhancing extracellular DA release in the striatum (Volkow et al., 2002; Wilens, 2008) and (2) indirectly increasing NE actions through blockade of its transporters (Berridge et al., 2006).”
From The Effects of Methylphenidate on Goal-directed Behavior in a Rat Model of ADHD (2015) · cites this paper as Wilens, 2008
In the citing paper
“there is increasing evidence of the relevance of catecholaminergic modulation in limbic regions such as ventral striatum (perhaps also amygdala and hippocampus) in mediating the motivation enhancing effects of stimulant drugs (Lehmann et al, 2003;Wilens, 2008).”
From Understanding the Effects of Stimulant Medications on Cognition in Individuals with Attention-Deficit Hyperactivity Disorder: A Decade of Progress (2011) · cites this paper as Wilens, 2008
In the citing paper
“Several brain regions and circuits are involved in the orchestration of specific cognitive processes that impact attention; these circuits are modulated by the catecholaminergic system and thus are affected and modulated by stimulant medications (Wilens, 2008).”
From Understanding the Effects of Stimulant Medications on Cognition in Individuals with Attention-Deficit Hyperactivity Disorder: A Decade of Progress (2011) · cites this paper as Wilens, 2008
Citations
Cites
Berridge, C. W., & Waterhouse, B. D. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00143-7 · Cited by 2,529
Bymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123
Two dopamine receptors: Biochemistry, physiology and pharmacology
Stoof, J. C., & Kebabian, J. W. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90519-8 · Cited by 939
Greenhill, L. L., Pliszka, S., & Dulcan, M. K. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200202001-00003 · Cited by 927
Modulation of neurotransmitter release by presynaptic autoreceptors
Starke, K., Gothert, M., & Kilbinger, H. (1989) · Physiological Reviews · doi:10.1152/physrev.1989.69.3.864 · Cited by 925
Volkow, N. D., Wang, G.-J., Fowler, J. S., Gatley, S. J., Logan, J., Ding, Y.-S., Hitzemann, R., & Pappas, N. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.10.1325 · Cited by 885
Trends in the Prescribing of Psychotropic Medications to Preschoolers
Zito, J. M. (2000) · JAMA · doi:10.1001/jama.283.8.1025 · Cited by 863 · cited 1×
“Between 1991 and 1995, stimulant use by preschoolers increased 3-fold.(3) Among the marketed stimulants, MPH and dextroamphetamine are the only medications licensed for ADHD in most countries.”
BackgroundVaidya, C. J., Austin, G., Kirkorian, G., Ridlehuber, H. W., Desmond, J. E., Glover, G. H., & Gabrieli, J. D. E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.24.14494 · Cited by 845 · cited 1×
“Specifically, MPH has been shown to modulate neuronal activity in the striatum during stimulus-controlled tasks involving motor inhibition.(17) Using functional magnetic resonance imaging (fMRI), Vaidya et al(17) demonstrated selective effects of MPH in children with ADHD compared with those without ADHD during the pe…”
BackgroundVolkow, N. D., Wang, G.-J., Fowler, J. S., Logan, J., Gerasimov, M., Maynard, L., Ding, Y.-S., Gatley, S. J., Gifford, A., & Franceschi, D. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-j0001.2001 · Cited by 770
Dopamine transporter density in patients with attention deficit hyperactivity disorder
Dougherty, D. D., Bonab, A. A., Spencer, T. J., Rauch, S. L., Madras, B. K., & Fischman, A. J. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04030-1 · Cited by 684
Berridge, C. W., Devilbiss, D. M., Andrzejewski, M. E., Arnsten, A. F. T., Kelley, A. E., Schmeichel, B., Hamilton, C., & Spencer, R. C. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.04.022 · Cited by 617
Mechanisms for selection of basic motor programs – roles for the striatum and pallidum
Grillner, S., Hellgren, J., Ménard, A., Saitoh, K., & Wikström, M. A. (2005) · Trends in Neurosciences · doi:10.1016/j.tins.2005.05.004 · Cited by 592
Volkow, N. D. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950180042006 · Cited by 575 · cited 1×
“Studies in human and baboon brains show that binding of d-threo-MPH is concentrated in the basal ganglia, whereas there are comparatively low levels of l-threo-MPH binding throughout the brain.(28,29) A large body of evidence based on positron emission tomography (PET) studies has shed further light on the distributio…”
BackgroundKrause, K.-H., Dresel, S. H., Krause, J., Kung, H. F., & Tatsch, K. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01040-5 · Cited by 521 · cited 1×
“7 ng/mL.(38) Thus, standard therapeutic doses of MPH block more than 50% of DATs.”
BackgroundSonders, M. S., Zhu, S.-J., Zahniser, N. R., Kavanaugh, M. P., & Amara, S. G. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-03-00960.1997 · Cited by 444
Han, D. D., & Gu, H. H. (2006) · BMC Pharmacology · doi:10.1186/1471-2210-6-6 · Cited by 419
Faraone, S. V., Spencer, T., Aleardi, M., Pagano, C., & Biederman, J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000108984.11879.95 · Cited by 404
The Dopamine Transporter and Attention-Deficit/Hyperactivity Disorder
Madras, B. K., Miller, G. M., & Fischman, A. J. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.10.011 · Cited by 393 · cited 1×
“In the cortex, where, unlike the striatum, concentrations of DAT are relatively low compared with NET, it has been postulated that DA is transported by the NET, for which it has greater affinity.(67) Thus, the NET may be a point of interaction of dopaminergic and noradrenergic systems.”
BackgroundFunctional role of the basal ganglia in the planning and execution of actions
Monchi, O., Petrides, M., Strafella, A. P., Worsley, K. J., & Doyon, J. (2006) · Annals of Neurology · doi:10.1002/ana.20742 · Cited by 380
Volkow, N. D., Wang, G.-J., Fowler, J. S., & Ding, Y.-S. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.006 · Cited by 368
Arnsten, A. F., & Dudley, A. G. (2005) · Behavioral and Brain Functions · doi:10.1186/1744-9081-1-2 · Cited by 363
Mechanism of action of methylphenidate: Insights from PET imaging studies
Volkow, N. D., Fowler, J. S., Wang, G., Ding, Y., & Gatley, S. J. (2002) · Journal of Attention Disorders · doi:10.1177/070674370200601s05 · Cited by 353 · cited 1×
“In the human brain, MPH has been shown to occupy and block the DAT,(36,40,46,47) amplifying the DA signal.(35) Dopamine transporter blockade by MPH is dose dependent in the striatum.”
BackgroundADHD Drugs and Cardiovascular Risk
Nissen, S. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068049 · Cited by 331
Volkow, N. D., Wang, G.-J., Newcorn, J., Telang, F., Solanto, M. V., Fowler, J. S., Logan, J., Ma, Y., Schulz, K., Pradhan, K., et al. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.8.932 · Cited by 331
Volkow, N. D., Wang, G., Fowler, J. S., Logan, J., Franceschi, D., Maynard, L., Ding, Y., Gatley, S. J., Gifford, A., Zhu, W., et al. (2002) · Synapse · doi:10.1002/syn.10038 · Cited by 321
KRATOCHVIL, C. J., HEILIGENSTEIN, J. H., DITTMANN, R., SPENCER, T. J., BIEDERMAN, J., WERNICKE, J., NEWCORN, J. H., CASAT, C., MILTON, D., & MICHELSON, D. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200207000-00008 · Cited by 292 · cited 1×
“The NET is also a target of the ADHD medication atomoxetine.(62) Methylphenidate effects on the NET are overall not well studied with respect to ADHD.”
BackgroundVolkow, N. D., Wang, G.-J., Fowler, J. S., Telang, F., Maynard, L., Logan, J., Gatley, S. J., Pappas, N., Wong, C., Vaska, P., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.7.1173 · Cited by 281
Dresel, S., Krause, J., Krause, K.-H., LaFougere, C., Brinkbäumer, K., Kung, H. F., Hahn, K., & Tatsch, K. (2000) · European Journal of Nuclear Medicine · doi:10.1007/s002590000330 · Cited by 278
Kuczenski, R., & Segal, D. S. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38829-9 · Cited by 267
Anti-hyperactivity medication: methylphenidate and amphetamine
Seeman, P., & Madras, B. K. (1998) · Molecular Psychiatry · doi:10.1038/sj.mp.4000421 · Cited by 252
Brain dopamine transporter levels in treatment and drug naive adults with ADHD
Volkow, N. D., Wang, G.-J., Newcorn, J., Fowler, J. S., Telang, F., Solanto, M. V., Logan, J., Wong, C., Ma, Y., Swanson, J. M., et al. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2006.10.014 · Cited by 249
WILENS, T. E., GIGNAC, M., SWEZEY, A., MONUTEAUX, M. C., & BIEDERMAN, J. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000199027.68828.b3 · Cited by 246
Self-citationNonmedical use of prescription stimulants in the United States
Kroutil, L. A., Van Brunt, D. L., Herman-Stahl, M. A., Heller, D. C., Bray, R. M., & Penne, M. A. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2005.12.011 · Cited by 233
Dittmann, R. W., Fouche, D. S., Kratochvil, C., Heiligenstein, J. H., Spencer, T., & Biederman, J. (2001) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(01)80448-x · Cited by 223
Volkow, N. (2002) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)00104-9 · Cited by 217
Gresch, P. J., Sved, A. F., Zigmond, M. J., & Finlay, J. M. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65010111.x · Cited by 208
Spencer, T. J., Biederman, J., E. Ciccone, P., Madras, B. K., Dougherty, D. D., Bonab, A. A., Livni, E., Parasrampuria, D. A., & Fischman, A. J. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.3.387 · Cited by 206
Gobert, A., Rivet, J.-M., Audinot, V, Newman-Tancredi, A., Cistarelli, L., & Millan, M. J. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00565-4 · Cited by 203
Breier, A., Adler, C. M., Weisenfeld, N., Su, T.-P., Elman, I., Picken, L., Malhotra, A. K., & Pickar, D. (1998) · Synapse · doi:10.1002/(sici)1098-2396(199806)29:2<142::aid-syn5>3.0.co;2-7 · Cited by 201
Moll, G. H., Heinrich, H., Trott, G.-E., Wirth, S., & Rothenberger, A. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)00980-0 · Cited by 198
Cheon, K.-A., Ryu, Y. H., Kim, Y.-K., Namkoong, K., Kim, C.-H., & Lee, J. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-1047-3 · Cited by 187
Spencer, T. J., Biederman, J., Madras, B. K., Faraone, S. V., Dougherty, D. D., Bonab, A. A., & Fischman, A. J. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.03.036 · Cited by 185
Wilens, T. E., & Biederman, J. (1992) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30265-x · Cited by 177
Self-citationWilens, T. E., & Decker, M. W. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.002 · Cited by 164
Self-citationWilens, T. E., & Spencer, T. J. (2000) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/s1056-4993(18)30108-1 · Cited by 164
Self-citationDing, Y.-S., Fowler, J. S., Volkow, N. D., Dewey, S. L., Wang, G.-J., Logan, J., Gatley, S. J., & Pappas, N. (1997) · Psychopharmacology · doi:10.1007/s002130050267 · Cited by 157 · cited 2×
“Studies in humans have shown that both oral and intravenous MPH is taken up by the brain, with d-threoMPH, but not l-threo-MPH, binding specifically to DAT proteins.(28) Studies in human and baboon brains show that binding of d-threo-MPH is concentrated in the basal ganglia, whereas there are comparatively low levels…”
BackgroundBoonstra, A. M., Kooij, J. J. S., Oosterlaan, J., Sergeant, J. A., & Buitelaar, J. K. (2005) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803390490515757 · Cited by 157
Kim, C.-H., Hahn, M. K., Joung, Y., Anderson, S. L., Steele, A. H., Mazei-Robinson, M. S., Gizer, I., Teicher, M. H., Cohen, B. M., Robertson, D., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510836103 · Cited by 154
Tepper, J. M., Sun, B.-C., Martin, L. P., & Creese, I. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-07-02519.1997 · Cited by 151
Unaltered Dopamine Transporter Availability in Adult Attention Deficit Hyperactivity Disorder
van Dyck, C. H., Quinlan, D. M., Cretella, L. M., Staley, J. K., Malison, R. T., Baldwin, R. M., Seibyl, J. P., & Innis, R. B. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.2.309 · Cited by 139
Rosa-Neto, P., Lou, H. C., Cumming, P., Pryds, O., Karrebaek, H., Lunding, J., & Gjedde, A. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2004.11.031 · Cited by 135
Okie, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068113 · Cited by 125
(2003) · Neuropediatrics · doi:10.1055/s-2003-39602 · Cited by 122
Tzavara, E. T., Bymaster, F. P., Overshiner, C. D., Davis, R. J., Perry, K. W., Wolff, M. C., McKinzie, D. L., Witkin, J. M., & Nomikos, G. G. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001763 · Cited by 121
Association of Norepinephrine Transporter Gene With Methylphenidate Response
Yang, L., Wang, Y., Li, J., & Faraone, S. V. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000131134.63368.46 · Cited by 117
Swanson, J. M., Gupta, S., Williams, L., AGLER, D., Lerner, M., & Wigal, S. B. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200211000-00011 · Cited by 106
WIGAL, S., SWANSON, J. M., FEIFEL, D., SANGAL, R. B., ELIA, J., CASAT, C. D., ZELDIS, J. B., & CONNERS, C. K. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000138351.98604.92 · Cited by 101
Methylphenidate Increases Cortical Excitability via Activation of Alpha-2 Noradrenergic Receptors
Andrews, G. D., & Lavin, A. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300818 · Cited by 101 · cited 1×
“In normal infant rats, MPH was found to significantly increase the excitability of cortical pyramidal neurons by enhancing catecholamine concentrations.(27) Studies in humans have shown that both oral and intravenous MPH is taken up by the brain, with d-threoMPH, but not l-threo-MPH, binding specifically to DAT protei…”
BackgroundGilbert, D. L., Ridel, K. R., Sallee, F. R., Zhang, J., Lipps, T. D., & Wassermann, E. M. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300806 · Cited by 97
Santosh, P. J., & Taylor, E. (2000) · European Child & Adolescent Psychiatry · doi:10.1007/s007870070017 · Cited by 94 · cited 2×
“Other neurotransmitters such as histamine, acetylcholine, serotonin, and !-agonists may play additional roles in ADHD pathophysiology.(4) For instance, blocking the H3 autoreceptors has been shown to improve cognitive function in animals through an increase in histamine release.”
BackgroundStimulants and Sudden Death: What Is a Physician to Do?
Wilens, T. E., Prince, J. B., Spencer, T. J., & Biederman, J. (2006) · Pediatrics · doi:10.1542/peds.2006-0942 · Cited by 88
Self-citationCrawford, C. A., McDougall, S. A., Meier, T. L., Collins, R. L., & Watson, J. B. (1998) · Psychopharmacology · doi:10.1007/s002130050536 · Cited by 85
Krause, J., la Fougere, C., Krause, K.-H., Ackenheil, M., & Dresel, S. H. (2005) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-005-0602-x · Cited by 84
PRACTICE PARAMETER FOR THE USE OF STIMULANT MEDICATIONS
Greenhill, L. L. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200210000-00003 · Cited by 77
Methylphenidate facilitates and disinhibits the motor cortex in intact humans
Ilić, T. V., Korchounov, A., & Ziemann, U. (2003) · NeuroReport · doi:10.1097/00001756-200304150-00023 · Cited by 74
Moll, G. H., Heinrich, H., & Rothenberger, A. (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2003.02114.x · Cited by 69
ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
Schweitzer, J. B., Cummins, T. K., & Kant, C. (2001) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70339-4 · Cited by 67
Methylphenidate and atomoxetine increase histamine release in rat prefrontal cortex
Horner, W. E., Johnson, D. E., Schmidt, A. W., & Rollema, H. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.11.048 · Cited by 57
Arnold, L. E., Lindsay, R. L., Conners, C. K., Wigal, S. B., Levine, A. J., Johnson, D. E., West, S. A., Sangal, R. B., Bohan, T. P., & Zeldis, J. B. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2004.14.542 · Cited by 51
Methylphenidate Enhances Both Intracortical Inhibition and Facilitation in Healthy Adults
Kirschner, J., Moll, G. H., Fietzek, U. M., Heinrich, H., Mall, V., Berweck, S., Heinen, F., & Rothenberger, A. (2003) · Pharmacopsychiatry · doi:10.1055/s-2003-39049 · Cited by 45
Drouin, C., Page, M., & Waterhouse, B. (2006) · Journal of Neurophysiology · doi:10.1152/jn.01310.2005 · Cited by 45
Easton, N., Shah, Y. B., Marshall, F. H., Fone, K. C. F., & Marsden, C. A. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0558-1 · Cited by 43
ADHD in adolescence and adulthood, with a special focus on the dopamine transporter and nicotine
Krause, J., Krause, K.-H., Dresel, S. H., la Fougère, C., & Ackenheil, M. (2006) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2006.8.1/jkrause · Cited by 38
Ishimatsu, M., Kidani, Y., Tsuda, A., & Akasu, T. (2002) · Journal of Neurophysiology · doi:10.1152/jn.00463.2001 · Cited by 28
Research works printed but not linked: 2
- Madras, 1998, Altropane, a SPECT or PET imaging probe for dopamine neurons: II. Distribution to dopamine-rich regions of primate brain., Synapse, 29, 105, 10.1002/(SICI)1098-2396(199806)29:2<105::AID-SYN2>3.0.CO;2-B · DOI
- Madras, 1998, Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain., Synapse, 29, 116, 10.1002/(SICI)1098-2396(199806)29:2<116::AID-SYN3>3.0.CO;2-A · DOI · Paper page
Cited by
del Campo, N., Chamberlain, S. R., Sahakian, B. J., & Robbins, T. W. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.02.036 · Cited by 685
Rubia, K., Halari, R., Cubillo, A., Mohammad, A.-M., Brammer, M., & Taylor, E. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.08.013 · Cited by 393
Rubia, K., Alegria, A. A., Cubillo, A. I., Smith, A. B., Brammer, M. J., & Radua, J. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.10.016 · Cited by 315
Treatment strategies for ADHD: an evidence-based guide to select optimal treatment
Caye, A., Swanson, J. M., Coghill, D., & Rohde, L. A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0116-3 · Cited by 303
Dichter, G. S., Damiano, C. A., & Allen, J. A. (2012) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-4-19 · Cited by 299
Metadata
- Authors
- Wilens, T. E.
- Affiliations
- Harvard University (US)
- Corresponding author
- Wilens, Timothy E.
- ORCID
- Wilens, Timothy E.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2008-06
- Volume
- 28
- Issue
- 3
- Pages
- S46-S53
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2077465062
- Cited by
- 269
- References
- 75
- Citations by year
- 2026: 11 · 2025: 5 · 2024: 7 · 2023: 8 · 2022: 12 · 2021: 11 · 2020: 12 · 2019: 14 · 2018: 17 · 2017: 16 · 2016: 22 · 2015: 19 · 2014: 20 · 2013: 15 · 2012: 29
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- methylphenidate, attention deficit hyperactivity disorder, catecholaminergic system, dopamine signaling, dopamine D2 autoreceptors, dopamine D1 receptor, prefrontal cortex, striatum, histamine, acetylcholine, serotonin, alpha-adrenergic agonists
- MeSH terms
- Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Child, Corpus Striatum, Dopamine, Humans, Methylphenidate, Nerve Net, Synaptic Transmission, Norepinephrine, Signal Transduction, Prefrontal Cortex, Receptors, Dopamine D1, Receptors, Dopamine D2, Receptors, Adrenergic, alpha-2, Dopamine Plasma Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.